Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Schibsted in conjunction with investment in Savr
Mandate

Vinge advises Schibsted in conjunction with investment in Savr

March 08, 2022 M&A Banking and Finance Intellectual Property

Vinge has advised Schibsted in conjunction with its investment in Savr AB. The investment round, which is headed by Schibsted, will cotribute SEK 162 million to the company. Savr is a fund platform which repays all fund commission to its customers.

Vinge’s team consisted primarily of Johan Winnerblad, Emma Stuart-Beck, Henrik Schön, Caroline Krassén, Anton Sjökvist and Sofia Bergenstråhle.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026